Literature DB >> 15986415

Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.

Anna S F Lok1, Marc G Ghany, Zachary D Goodman, Elizabeth C Wright, Gregory T Everson, Richard K Sterling, James E Everhart, Karen L Lindsay, Herbert L Bonkovsky, Adrian M Di Bisceglie, William M Lee, Timothy R Morgan, Jules L Dienstag, Chihiro Morishima.   

Abstract

Knowledge of the presence of cirrhosis is important for the management of patients with chronic hepatitis C (CHC). Most models for predicting cirrhosis were derived from small numbers of patients and included subjective variables or laboratory tests that are not readily available. The aim of this study was to develop a predictive model of cirrhosis in patients with CHC based on standard laboratory tests. Data from 1,141 CHC patients including 429 with cirrhosis were analyzed. All biopsies were read by a panel of pathologists (blinded to clinical features), and fibrosis stage was determined by consensus. The cohort was divided into a training set (n = 783) and a validation set (n = 358). Variables that were significantly different between patients with and without cirrhosis in univariate analysis were entered into logistic regression models, and the performance of each model was compared. The area under the receiver-operating characteristic curve of the final model comprising platelet count, AST/ALT ratio, and INR in the training and validation sets was 0.78 and 0.81, respectively. A cutoff of less than 0.2 to exclude cirrhosis would misclassify only 7.8% of patients with cirrhosis, while a cutoff of greater than 0.5 to confirm cirrhosis would misclassify 14.8% of patients without cirrhosis. The model performed equally well in fragmented and nonfragmented biopsies and in biopsies of varying lengths. Use of this model might obviate the requirement for a liver biopsy in 50% of patients with CHC. In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986415     DOI: 10.1002/hep.20772

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  96 in total

1.  Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C.

Authors:  Jae Youn Cheong; Soon Ho Um; Yeon Seok Seo; Dong Joon Kim; Seong Gyu Hwang; Youn Jae Lee; Mong Cho; Jin Mo Yang; Young Bae Kim; Young Nyun Park; Sung Won Cho
Journal:  Dig Dis Sci       Date:  2010-06-29       Impact factor: 3.199

2.  Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study.

Authors:  J Cui; B Ang; W Haufe; C Hernandez; E C Verna; C B Sirlin; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2015-04-15       Impact factor: 8.171

Review 3.  Liver elastography, comments on EFSUMB elastography guidelines 2013.

Authors:  Xin-Wu Cui; Mireen Friedrich-Rust; Chiara De Molo; Andre Ignee; Dagmar Schreiber-Dietrich; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

Review 4.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

5.  Comparison of circulating endothelial cell/platelet count ratio to aspartate transaminase/platelet ratio index for identifying patients with cirrhosis.

Authors:  Saurabh Sethi; Douglas A Simonetto; Soha S Abdelmoneim; Michael B Campion; Irakli Kaloiani; Amy C Clayton; Walter K Kremers; Kevin C Halling; Patrick S Kamath; Jayant Talwalkar; Vijay H Shah
Journal:  J Clin Exp Hepatol       Date:  2012-04-12

6.  Non invasive tools for the diagnosis of liver cirrhosis.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Melchiorre Cervello; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

7.  A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C.

Authors:  G Shiha; S Seif; A Eldesoky; M Elbasiony; R Soliman; A Metwally; K Zalata; N Mikhail
Journal:  Hepatol Int       Date:  2017-04-19       Impact factor: 6.047

8.  Association of γ-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV).

Authors:  James E Everhart; Elizabeth C Wright
Journal:  Hepatology       Date:  2013-04-05       Impact factor: 17.425

9.  Comparison of liver biopsy and transient elastography based on clinical relevance.

Authors:  Ryota Masuzaki; Ryosuke Tateishi; Haruhiko Yoshida; Erik Goto; Takahisa Sato; Takamasa Ohki; Tadashi Goto; Hideo Yoshida; Fumihiko Kanai; Yosuke Sugioka; Hitoshi Ikeda; Shuichiro Shiina; Takao Kawabe; Masao Omata
Journal:  Can J Gastroenterol       Date:  2008-09       Impact factor: 3.522

Review 10.  Non-invasive diagnosis of hepatitis B virus-related cirrhosis.

Authors:  Sangheun Lee; Do Young Kim
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.